XADAGO (safinamide) is a once-daily tablet for Parkinson’s disease patients as an add-on to levodopa/carbidopa who are experiencing “off” episodes, providing “on” time without
Recruitment for potentially pivotal study in patients suffering from Rett syndrome ongoing in the USA, Europe, Asia and Australia
Milan, Italy and Morristown, N.J., USA – May 17,
Milan, Italy, May 12, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy, April 11, 2017 (World Parkinson’s Day*) – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Zambon today announces the availability of Xadago® (safinamide) in Portugal as an add-on to levodopa alone or in combination with other Parkinson’s disease (PD) medications in
Milan, Italy, April 5, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milano, Italy – 28 March 2017 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of
Evenamide met study objectives of good tolerability, safety, and preliminary evidence of efficacy as an add-on therapy for the treatment of schizophrenia
Unique mechanism:
First New Chemical Entity (NCE) approved for PD patients with motor fluctuations in the U.S.A. in over a decade
Milan, Italy and Morristown, NJ, U.S.A., – March 21, 2017 – Newron
Phase 2 study evaluated safety, tolerability, and preliminary evidence of efficacy of Evenamide (NW-3509) as an add-on to antipsychotics in patients with schizophrenia
Milan,
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
